| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Qiong Liu | Q89992805 |
| P2093 | author name string | Ruizhen Li | |
| Xiaotian Huang | |||
| Yingxuan Zhang | |||
| Zheyan Fang | |||
| P2860 | cites work | Export of virulence genes and Shiga toxin by membrane vesicles of Escherichia coli O157:H7 | Q24550568 |
| Bacterial outer membrane vesicles and vaccine applications | Q24568229 | ||
| Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 | Q24611404 | ||
| Outer membrane vesicles as platform vaccine technology | Q26766539 | ||
| Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi | Q26795676 | ||
| Routes and mechanisms of extracellular vesicle uptake | Q27023027 | ||
| Macropinosomes are Key Players in Early Shigella Invasion and Vacuolar Escape in Epithelial Cells | Q27314121 | ||
| Mechanisms of outer membrane vesicle entry into host cells | Q28071348 | ||
| Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice | Q28482083 | ||
| Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models | Q28539933 | ||
| Nanocarriers as an emerging platform for cancer therapy | Q29616699 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A. | Q33598183 | ||
| Virulence and immunomodulatory roles of bacterial outer membrane vesicles | Q33704480 | ||
| Delivery of foreign antigens by engineered outer membrane vesicle vaccines | Q33733590 | ||
| An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. | Q33773435 | ||
| Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors | Q33870710 | ||
| Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors | Q33898615 | ||
| Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate | Q34004684 | ||
| Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen | Q34037511 | ||
| Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response | Q34056091 | ||
| Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. | Q34109882 | ||
| Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. | Q34357503 | ||
| Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake | Q34382612 | ||
| Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. | Q34529570 | ||
| Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2. | Q34558230 | ||
| Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. | Q34607625 | ||
| A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models | Q34607646 | ||
| Therapeutic cancer vaccines: are we there yet? | Q34786691 | ||
| The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. | Q35009076 | ||
| A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection | Q35375333 | ||
| Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. | Q35419821 | ||
| Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice | Q35549844 | ||
| Colitogenic Bacteroides thetaiotaomicron Antigens Access Host Immune Cells in a Sulfatase-Dependent Manner via Outer Membrane Vesicles | Q35608009 | ||
| Immunization of mice with vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission | Q35669021 | ||
| Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth | Q39960374 | ||
| Development of a Listeria monocytogenes based vaccine against prostate cancer. | Q40013300 | ||
| Structure, function, and assembly of cell walls of gram-positive bacteria | Q40092142 | ||
| A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis | Q40177462 | ||
| Outer Membrane Vesicles Derived from Salmonella Enteritidis Protect against the Virulent Wild-Type Strain Infection in a Mouse Model. | Q40200619 | ||
| Relation Between Excreted Lipopolysaccharide Complexes and Surface Structures of a Lysine-Limited Culture of Escherichia coli | Q40244803 | ||
| Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein | Q40290133 | ||
| Clostridium difficile-derived membrane vesicles induce the expression of pro-inflammatory cytokine genes and cytotoxicity in colonic epithelial cells in vitro | Q40298164 | ||
| Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain. | Q40791154 | ||
| Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles | Q40821392 | ||
| Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. | Q41077558 | ||
| Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. | Q41428160 | ||
| Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. | Q41701099 | ||
| TG4010: A therapeutic vaccine against MUC1 expressing tumors | Q41819414 | ||
| Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor | Q41830085 | ||
| IL-18-producing Salmonella inhibit tumor growth | Q42000711 | ||
| Growth-phase-dependent expression of the operon coding for the glycosylated autotransporter adhesin AIDA-I of pathogenic Escherichia coli | Q42910871 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. | Q44073787 | ||
| Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1. | Q44187578 | ||
| Engineered Salmonella typhimurium expressing E7 fusion protein, derived from human papillomavirus, inhibits tumor growth in cervical tumor-bearing mice | Q44678997 | ||
| Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth | Q45857897 | ||
| Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma | Q45867131 | ||
| Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium | Q45882037 | ||
| Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth | Q45883318 | ||
| Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment | Q45883842 | ||
| Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles | Q47095060 | ||
| Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin | Q47587450 | ||
| Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine | Q47629539 | ||
| Engineering multi-functional bacterial outer membrane vesicles as modular nanodevices for biosensing and bioimaging | Q47998962 | ||
| A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model. | Q48158997 | ||
| Cancer vaccine strategies: translation from mice to human clinical trials. | Q48295639 | ||
| Personalized cancer vaccines: Targeting the cancer mutanome | Q49956120 | ||
| Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma | Q49959179 | ||
| Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model | Q50025263 | ||
| Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen | Q50041387 | ||
| Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis | Q50058791 | ||
| Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic | Q50066080 | ||
| Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo | Q50066630 | ||
| Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin | Q50102555 | ||
| Immunotherapy: Cancer vaccines on the move | Q50141307 | ||
| Clostridium as a tumor-specific delivery system of therapeutic proteins. | Q51709847 | ||
| Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. | Q51983228 | ||
| Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. | Q53115452 | ||
| Gram-positive bacteria produce membrane vesicles: proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles. | Q53494011 | ||
| Immunization With Skp Delivered on Outer Membrane Vesicles Protects Mice Against Enterotoxigenic Escherichia coli Challenge. | Q54202193 | ||
| Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. | Q54297240 | ||
| Effects of the Escherichia coli toxin cytolysin A on mucosal immunostimulation via epithelial Ca2+ signalling and Toll-like receptor 4. | Q54486263 | ||
| Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants. | Q55380286 | ||
| Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Q56899396 | ||
| Therapeutic cancer vaccine: building the future from lessons of the past | Q57177129 | ||
| Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells | Q57272367 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice | Q63253481 | ||
| Recent Advances in Cancer Stem Cell-Targeted Immunotherapy | Q64061376 | ||
| A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against , Including Pertactin Deficient Strains | Q64084683 | ||
| Flagellin-deficient outer membrane vesicles as adjuvant induce cross-protection of Salmonella Typhimurium outer membrane proteins against infection by heterologous Salmonella serotypes | Q89408218 | ||
| Toll-Like Receptors 2 and 4 Modulate Pulmonary Inflammation and Host Factors Mediated by Outer Membrane Vesicles Derived from Acinetobacter baumannii | Q91527811 | ||
| Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract | Q91641232 | ||
| Combinational Effects of Active Targeting, Shape, and Enhanced Permeability and Retention for Cancer Theranostic Nanocarriers | Q91824276 | ||
| Immunotherapy in breast cancer: Current status and future directions | Q92768554 | ||
| From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy | Q92768567 | ||
| Prospects for a personalized peptide vaccine against lung cancer | Q92935458 | ||
| Can Dendritic Cell Vaccination Prevent Leukemia Relapse? | Q92990818 | ||
| Cancer immunotherapy: the art of targeting the tumor immune microenvironment | Q93032171 | ||
| Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles | Q37880078 | ||
| Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. | Q37981764 | ||
| Live-attenuated bacteria as a cancer vaccine vector | Q38152473 | ||
| Immune response to sipuleucel-T in prostate cancer | Q38161390 | ||
| Protein selection and export via outer membrane vesicles | Q38174010 | ||
| Are caveolae a cellular entry route for non-viral therapeutic delivery systems? | Q38314453 | ||
| Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression | Q38421791 | ||
| Immune modulation by bacterial outer membrane vesicles. | Q38481554 | ||
| Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma | Q38534285 | ||
| Prospect of rindopepimut in the treatment of glioblastoma. | Q38748694 | ||
| Advances in Therapeutic Cancer Vaccines | Q38753394 | ||
| Vaccines for established cancer: overcoming the challenges posed by immune evasion | Q38769021 | ||
| Combined prokaryotic-eukaryotic delivery and expression of therapeutic factors through a primed autocatalytic positive-feedback loop | Q38810736 | ||
| Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. | Q39143931 | ||
| Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | Q39207345 | ||
| Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma | Q39360242 | ||
| Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors | Q39378919 | ||
| Outer Membrane Vesicles (OMVs) of Gram-negative Bacteria: A Perspective Update | Q39397693 | ||
| Elicitation of epithelial cell-derived immune effectors by outer membrane vesicles of nontypeable Haemophilus influenzae | Q39482528 | ||
| Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer. | Q39623623 | ||
| The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls | Q39644429 | ||
| Uptake of Helicobacter pylori outer membrane vesicles by gastric epithelial cells. | Q39650801 | ||
| Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human | Q39665364 | ||
| Attenuated Salmonella typhimurium carrying TRAIL and VP3 genes inhibits the growth of gastric cancer cells in vitro and in vivo. | Q39689133 | ||
| Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis | Q39745755 | ||
| Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer | Q39760012 | ||
| Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth | Q35921725 | ||
| Engineered bacterial outer membrane vesicles with enhanced functionality | Q36198257 | ||
| Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity | Q36294442 | ||
| The rationale for prophylactic cancer vaccines and need for a paradigm shift | Q36423899 | ||
| Incorporation of Heterologous Outer Membrane and Periplasmic Proteins into Escherichia coli Outer Membrane Vesicles | Q36475788 | ||
| Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth | Q36476449 | ||
| Overview of the cancer vaccine field: are we moving forward? | Q36552930 | ||
| Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial cells in a NOD1 protein-dependent manner and induce dendritic cell-mediated Th2/Th17 cell responses | Q36596316 | ||
| New technologies in developing recombinant attenuated Salmonella vaccine vectors | Q36653379 | ||
| Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma | Q36657731 | ||
| Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL. | Q36707828 | ||
| Inhibition of tumor growth using salmonella expressing Fas ligand | Q36812613 | ||
| L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors | Q36838520 | ||
| L-BLP25: a peptide vaccine strategy in non small cell lung cancer | Q36899928 | ||
| Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies | Q36949433 | ||
| Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct | Q37059663 | ||
| RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy | Q37112974 | ||
| Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro | Q37141141 | ||
| Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors in mice | Q37201418 | ||
| Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles | Q37222609 | ||
| Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge | Q37307095 | ||
| HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women | Q37315939 | ||
| EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells | Q37372414 | ||
| Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. | Q37424066 | ||
| Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium | Q37451801 | ||
| Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles | Q37476252 | ||
| Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future | Q37514748 | ||
| Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions | Q37641231 | ||
| Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells | Q37729987 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives | Q37808234 | ||
| An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines | Q37842893 | ||
| Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach | Q37843964 | ||
| Macropinocytosis: an endocytic pathway for internalising large gulps | Q37855532 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P921 | main subject | vaccine engineering | Q14861085 |
| P577 | publication date | 2019-09-06 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy | |
| P478 | volume | 11 |
| Q92702538 | Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona | cites work | P2860 |
Search more.